Ann: Updated investor presentation and attendance at Bioshares, page-56

Merck's Keytruda tops $2 billion in quarterly sales, shares rise
Published 7:12 AM ET Fri, 1 Feb 2019
- Merck & Co's cancer immunotherapy Keytruda reported sales that topped $2 billion in a quarter for the first time, exceeding Wall Street's lofty estimates and sending shares up more that 3 percent on Friday.
- Keytruda has been Merck's most important growth driver with its domination of the lucrative lung cancer space, and shows no sign of slowing as it produces positive clinical data and adds approvals for different types of cancer.
https://www.cnbc.com/amp/2019/02/01/merck-earnings-q4-2018-.html

It seems to me PAT-DX1&NP have similar (or even better) potential to be actualised in the next few years, given it is the world's first cell-penetrating & BBB-crossing antibody platform targeting different types of cancer and other various applications, and it has obvious first-mover advantages with its uniqueness and strong IP position worldwide.